Dr. Xu Liangliang received his undergraduate and doctoral degrees from the Department of Biological Sciences and Technology and the School of Medicine of Tsinghua University (2000-2012), and worked at the Institute of Biomedicine and Health of the Chinese Academy of Sciences from 2012-2013. He returned to China in 2014 to start his own business. Founded in 2015, Forward Pharmaceuticals Co., Ltd has independently developed several new drug products including "the fourth generation of non-small cell lung cancer targeted drug", and has completed three rounds of marketize equity financing, raising nearly RMB 100 million. Dr. Xu Liangliang has applied for 12 patents for drug inventions (3 of them have been granted). He has been awarded with personal honors and government projects such as Pearl River Talents(Entrepreneurial leader) of Guangdong Province, Shenzhen Overseas High-Level Talents (Class B), Nanshan District Navigator Talents, Second Prize of Shenzhen Entrepreneurship Support Program for Overseas Students, and "Navigator Plan" High-Level Talents Entrepreneurship Support Program. He is also the Executive Director of the Anti-tumor Innovative Drug Development Center of Tsinghua University Research Institute in Shenzhen, the Director of Guangdong Small Molecule New Drug Innovation Center and the Director of Shenzhen Life Science and Biotechnology Association. Dr. Xu Liangliang is a self-employed entrepreneur with a scientific background, who has achieved results in two distinct fields: basic research and industrial transformation.